Zacks: Brokerages Anticipate Gilead Sciences, Inc. (GILD) to Announce $1.65 EPS

Equities research analysts expect that Gilead Sciences, Inc. (NASDAQ:GILD) will report $1.65 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Gilead Sciences’ earnings, with estimates ranging from $1.29 to $1.98. Gilead Sciences reported earnings per share of $2.70 during the same quarter last year, which suggests a negative year over year growth rate of 38.9%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Tuesday, February 6th.

According to Zacks, analysts expect that Gilead Sciences will report full year earnings of $8.71 per share for the current year, with EPS estimates ranging from $8.36 to $9.06. For the next year, analysts anticipate that the firm will report earnings of $6.76 per share, with EPS estimates ranging from $6.03 to $7.55. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.75 earnings per share.

Several research analysts have recently weighed in on GILD shares. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $85.53.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 591,666 shares of company stock worth $44,466,567 over the last ninety days. Insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Welch Investments LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences in the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences in the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management increased its holdings in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences (GILD) traded down $0.19 during trading on Tuesday, hitting $80.98. 6,970,543 shares of the stock traded hands, compared to its average volume of 8,120,000. The firm has a market capitalization of $105,750.00, a PE ratio of 9.21, a PEG ratio of -1.77 and a beta of 1.13. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.57%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.

COPYRIGHT VIOLATION WARNING: This story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/02/11/zacks-brokerages-anticipate-gilead-sciences-inc-gild-to-announce-1-65-eps.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply